Compare Crispr Therapeutics AG (CRSP) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Xylem, Inc. — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while Xylem, Inc. trades at $102.71 (market cap $23.81B). The key difference: Xylem, Inc. is far larger — about 4.9× Crispr Therapeutics AG's market cap, and Xylem, Inc. pays a 1.69% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Xylem, Inc. for 50 Days on average.
| CRSP | XYL | |
|---|---|---|
Market Cap | $4.88B | $23.81B |
Volume | 2,861,747 | 2,234,713 |
Sector | Health | Industrials |
52-Week High | $73.97 | $152.95 |
52-Week Low | $44.34 | $100.92 |
Typical Hold Time | 77 Days | 50 Days |
Enterprise Value | $3.30B | $25.59B |
Dividend Yield | — | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 3.65% amid bearish technical signals. The company shows negative profitability with -$581.60M net income and -4,101.26% net margin for 2025, though Q2 2026 EPS beat expectations. Positive analyst sentiment persists with 57.9% buy ratings and $67.83 consensus target. Recent clinical data presentations and CASGEVY commercial progress provide catalysts.
The stock faces fundamental challenges with persistent losses and negative cash flow from operations, but maintains Wall Street support for its gene-editing pipeline. Key risks include clinical trial outcomes and cash burn, while potential upside hinges on successful drug commercialization and upcoming data readouts through 2026.
XYL trades at $101.99, up 0.16% on the day, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results expected on October 27, 2026. Revenue grew to $9.04B in 2025, and net income margin improved to 10.59%. Recent acquisitions of Cornell Pump and Roper Pump aim to strengthen its industrial water solutions presence.
The outlook is supported by solid fundamentals and a consensus price target of $149.13, implying significant upside. Risks include China market weakness and higher debt from recent note offerings. Analyst sentiment is mixed with 47.5% buy ratings, but institutional interest remains strong, as seen in Bank of America's new position in Q2 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
